Last updated: February 15, 2026
Litigation Summary and Analysis: Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (1:11-cv-02037)
Case Overview
Purdue Pharma L.P. filed suit against Teva Pharmaceuticals USA, Inc. in the United States District Court for the District of Delaware in 2011. The case involves allegations of patent infringement related to generic versions of Purdue’s opioid medications. Purdue claims Teva’s proposed generic infringers violate its patents covering Purdue’s controlled-release formulations of oxycodone.
Key Patent Disputes
Purdue’s core patent, U.S. Patent No. 7,674,927, covers a controlled-release oxycodone formulation. Purdue obtained the patent in 2010, with a validity period that extends into 2028. Purdue argued that Teva's generic product, submitted via an Abbreviated New Drug Application (ANDA), infringed this patent under 35 U.S.C. § 271(e)(2).
Litigation Timeline
- 2011: Purdue filed suit shortly after Teva submitted its ANDA in 2010.
- 2012: Teva responded with a generic patent challenge under the Hatch-Waxman framework, asserting the patent was invalid or not infringed.
- 2014: District Court issued a preliminary injunction blocking Teva from marketing its generic until patent validity was resolved.
- 2015: Trial on patent infringement and validity issues was scheduled.
- 2016: The court concluded that Purdue’s patent was valid and enforceable but limited damages to past infringement, as Teva’s generic launch was delayed due to the injunction.
Patent Validity and Infringement
- Validity: The court found Purdue's patent sufficiently detailed and non-obvious based on the evidence presented, affirming its enforceability.
- Infringement: The court determined Teva's generic formulations infringed the patent by utilizing identical controlled-release technology.
Patent Litigation Strategies
Purdue relied on patent claims to extend market exclusivity, initiating litigation to block Teva from launching generic oxycodone. Teva’s defense challenged the patent's validity, asserting prior art invalidated the claims. The litigants engaged in extensive expert testimony on formulation chemistry and patent law.
Settlement and Market Impact
The case did not result in a settlement prior to the court’s final decision. The district court's injunction delayed Teva’s entry into the market until 2016, after the patent expiration date. In 2016, Teva launched its generic oxycodone, which subsequently faced patent challenges and market competition.
Key Legal Findings
- The court upheld Purdue's patent as valid and infringed upon by Teva.
- Injunctive relief was granted to prevent Teva's market entry until patent expiration or licensing settlement.
- The case reinforced the validity of Purdue’s formulation patents in the context of the opioid market.
Impact on the Industry
This litigation exemplifies the typical strategy of brand-name opioid manufacturers to enforce patent rights against generic entrants. It highlights judicial willingness to uphold patents covering complex drug formulations, particularly with high-value medications like opioids.
Key Takeaways
- Purdue successfully delayed generic market entry through patent litigation from 2011 to 2016.
- The case emphasizes the strength of Purdue’s formulation patent, upheld after challenge.
- The delayed entry impacted generic competition, maintaining higher prices.
- Patent enforcement remains a critical strategy for brand pharmaceutical companies facing generic competition.
- The case underscores jurisdictional reliance on patent validity assessments for market exclusivity.
Frequently Asked Questions
1. What priority did Purdue defend in this litigation?
Purdue aimed to uphold its patent rights to prevent generic competition for oxycodone formulations until patent expiration or licensing.
2. How did the court evaluate the validity of Purdue's patent?
The court examined prior art, formulation details, and non-obviousness, ultimately affirming the patent’s validity due to its inventive formulation approach.
3. Did Teva's generic oxycodone ever reach the market during the litigation?
Teva was barred from marketing its generic until 2016, when the injunction was lifted after the patent expired.
4. How does this case influence future patent disputes in the pharmaceutical industry?
It demonstrates courts' willingness to uphold patent claims for complex formulations and serve as a safeguard against patent challenge tactics.
5. What implications does this case have on opioid market competition?
It temporarily delayed generic access, preserving Purdue’s market share and pricing stability, thus impacting overall competition and accessibility.
Citations
- Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc., 1:11-cv-02037 (D. Del. 2011).
